CNC

Business profile & competitive position

Centene Corporation (CNC) sits in the Healthcare sector, specifically the Medical – Healthcare Plans industry. The company describes itself as the nation’s largest managed care organization focused on underserved populations. It delivers Medicaid, Medicare Advantage, Prescription Drug Plans (PDP), Medicare Supplement products, and commercial plans through the Health Insurance Marketplace. Centene operates through local brands supported by national infrastructure, and beyond traditional medical coverage it connects members with supports such as food, housing, utilities, and transportation.

The scale numbers back up the “largest” claim. For 2025, total revenues reached $194.8 billion, with the mix split 57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other. As of December 31, 2025, membership totaled 27.6 million: 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Centene is the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone PDP provider in the United States.

Yet the current margin picture does not match that dominant market position. The company’s net margin is −2.6% and return on equity is −24.0%. Those figures imply that scale has not recently translated into bottom-line profitability or attractive capital returns. A moat built on enrollment density and government-program specialization can produce stable cash flow in normal times—2025 operating cash flow was $5.1 billion—but it also exposes the business to regulatory pricing pressure and medical-cost spikes that can swing reported earnings sharply negative.

Financial posture

Centene’s current financial posture is that of a large, low-valuation managed-care name with negative trailing earnings. Market capitalization stands at $33.1 billion. The trailing P/E ratio is −6.4, a direct consequence of the −2.6% net margin and −24.0% ROE; when net income is negative, the P/E multiple loses its usual interpretive power and signals a turnaround/value debate rather than a steady-state valuation.

The stock’s beta is 1.11, meaning it has exhibited roughly 11% more systematic volatility than the broad market. At the time of this snapshot the share price was $67.04, the RSI was 55.7, and the 50-day exponential moving average was $64.24. Those technical data points place the stock slightly above its medium-term moving average but not in overbought territory. Taken together, the metric set describes a company with enormous revenue scale and member scale that is currently earning negative returns, leaving valuation dependent on whether management can restore margin and convert revenue back into net income.

Strategic priorities & outlook

Centene’s most recent 10-K filing outlines a near-term agenda built around three interlocking themes: refining Medicare, fixing Marketplace pricing, and aligning with regulatory timelines.

On the Medicare side, the company wants to overlap its Medicare footprint more closely with its Medicaid operations and expand Dual-Eligible Special Needs Plans (D-SNP) as a long-term growth driver. It is maintaining an enterprise-level focus on D-SNP, including integrated products aligned with CMS requirements that take effect through 2030. That long regulatory runway suggests D-SNP integration is not a one-year fix but a multi-year structural project.

On the commercial/Marketplace side, Centene plans to implement corrective 2026 pricing actions in states covering 95% of Marketplace membership and to expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states. The company also says it will advocate for policies and legislation aimed at preserving affordable Medicaid and Marketplace coverage and supporting cost-effective, high-quality PDP care.

Operationally, Centene signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses, continuing a portfolio-shaping effort.

Macro & geopolitical exposure

As a Healthcare Plans company, Centene’s economics are tightly coupled to government policy and regulated reimbursement. Medicaid is funded jointly by federal and state governments, so the company is exposed to state budget pressures, federal matching-rate changes, and any legislation that expands or contracts eligibility. Medicare Advantage and PDP revenues depend on CMS rate announcements, star-ratings adjustments, and rules that extend several years into the future—the 2030 CMS requirement timeline cited in the 10-K is a concrete example.

Broader healthcare inflation also matters directly because premium adequacy depends on how accurately the company prices medical-cost trends. Pharmacy costs, hospital utilization, and labor shortages in the care-delivery system can all compress margins if not priced into contracts. Healthcare reform debates, Affordable Care Act litigation or legislation, and federal debt-ceiling or government-funding standoffs can create headline volatility for any insurer dependent on federally backed products. Currency and physical supply-chain risks are less central here than they are for manufacturers or multinationals; for Centene, the dominant macro channels are regulation, reimbursement, medical-cost inflation, and state/federal fiscal health.

Recent developments

Centene has drawn steady attention in early September 2026. On September 4, 2026, Zacks published “Here’s Why Centene (CNC) is a Strong Value Stock,” and the same day Zacks also included CNC in “4 Stocks Trading Near 52-Week High With Room to Rise Further.” A day earlier, on September 3, 2026, Zacks asked “How Can Healthcare Inflation Fuel Growth for MRSH, UNH & CNC?”—grouping Centene with Marsh McLennan and UnitedHealth as names that could be affected by healthcare inflation dynamics.

One headline in the captured feed, dated September 7, 2026 from Proactive Investors, concerned Cavendish raising its target price for Concurrent Technologies rather than Centene, so it is best read as unrelated cross-ticker noise in the data feed rather than a Centene-specific item. The consistent Zacks coverage, however, shows sell-side commentary framing CNC as a value candidate with technical momentum near 52-week highs.

Earnings behavior & post-earnings drift

Centene’s recent earnings record is one of consistent beats against the official consensus. Over the last 8 reported quarters, the company has beaten 7 times for an 88% beat rate, with an average earnings surprise of 63.1%. Despite those headline beats, the immediate next-day price reaction has been uneven. Across the last four quarters, the average 5-trading-day post-earnings drift has been +2.83%, classified as an “up” drift.

The quarter-by-quarter picture shows how large surprises do not guarantee a positive next-day move. On October 29, 2025, Centene reported actual EPS of $0.50 against an estimate of −$0.14475, a 445.4% surprise, yet the stock fell 6.21% the next day and was down 1.34% over the following five sessions. On February 6, 2026, a narrow 2.5% beat on a loss of −$1.19 versus −$1.22007 produced a −1.09% next-day drop but a +5.51% five-day drift. The April 28, 2026 report—actual EPS $3.37 versus estimate $2.23, a 51.1% surprise—drove a +8.9% next-day pop and a +6.88% five-day gain, while the July 28, 2026 report—actual EPS $2.51 versus estimate $1.09, a 130.3% surprise—saw the stock fall 3.27% the next day and rise only 0.25% over the next five sessions.

The next scheduled report is October 27, 2026, before the open, with the consensus EPS estimate at just $0.07. That low bar reflects the current margin pressure and helps explain why even modest absolute results could register as large percentage surprises.

For a deeper look at how institutional analysts are weighing Centene’s turnaround prospects, valuation compression, and the upcoming earnings setup, see the full institutional verdict on the ticker page.